Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “JAK Inhibitor”

199 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 199 results

Not applicableEnrolling By InvitationNCT06999941
What this trial is testing

A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features

Who this might be right for
PsoriasisEczemaJAK Inhibitor
Xi Tan 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT04496960
What this trial is testing

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

Who this might be right for
Sjogren's Syndrome
National Institute of Dental and Craniofacial Research (NIDCR) 23
Not applicableNot Yet RecruitingNCT07211932
What this trial is testing

Tofacitinib in Juvenile Idiopathic Arthritis

Who this might be right for
Juvenile Idiopathic Arthritis (JIA)
Consorci Sanitari de l'Alt Penedès i Garraf 58
Not applicableWithdrawnNCT05177471
What this trial is testing

Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease

Who this might be right for
Systemic SclerosisInterstitial Lung Disease
Central Hospital, Nancy, France
Not applicableNot Yet RecruitingNCT07406932
What this trial is testing

A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome

Who this might be right for
Antisynthetase SyndromeInterstitial Lung Disease (ILD)
China-Japan Friendship Hospital 80
Testing effectiveness (Phase 2)Study completedNCT02164500
What this trial is testing

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

Who this might be right for
Recurrent Classical Hodgkin Lymphoma
University of Cologne 12
Testing effectiveness (Phase 2)Study completedNCT03921554
What this trial is testing

JAK Inhibitor Treatment in AGS

Who this might be right for
Aicardi Goutieres Syndrome
Adeline Vanderver, MD 54
Not applicableLooking for participantsNCT06573593
What this trial is testing

Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

Who this might be right for
Alopecia AreataJanus Kinase Inhibitors
Second Affiliated Hospital, School of Medicine, Zhejiang University 150
Large-scale testing (Phase 3)Study completedNCT02281552
What this trial is testing

Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis

Who this might be right for
Rheumatoid Arthritis
Pfizer 209
Not applicableNot Yet RecruitingNCT06977035
What this trial is testing

Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib

Who this might be right for
Rheumatoid Arthritis
Sohag University 60
Large-scale testing (Phase 3)Active Not RecruitingNCT04717414
What this trial is testing

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Who this might be right for
Myeloproliferative DisordersMyelofibrosisPrimary Myelofibrosis+2 more
Celgene 313
Very early researchNot Yet RecruitingNCT06414681
What this trial is testing

Combination of Tagraxofusp with Pacritinib in Patients with Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy with the Approved JAK Inhibitors or in Which Therapy with the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Who this might be right for
Myelofibrosis，MF
University of Kansas Medical Center 20
Not applicableUnknownNCT04530305
What this trial is testing

Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor

Who this might be right for
Rheumatoid Arthritis
University Hospital, Montpellier 60
Testing effectiveness (Phase 2)Study completedNCT04071366
What this trial is testing

Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Who this might be right for
Cytokine Release Syndrome
Incyte Corporation 112
Large-scale testing (Phase 3)Study completedNCT06238817
What this trial is testing

Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

Who this might be right for
Atopic Dermatitis
Incyte Corporation 241
Testing effectiveness (Phase 2)Study completedNCT02426086
What this trial is testing

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Who this might be right for
Myelofibrosis
Geron Corporation 107
Testing effectiveness (Phase 2)Active Not RecruitingNCT05393674
What this trial is testing

Fedratinib in Combination With Nivolumab

Who this might be right for
Primary MyelofibrosisSecondary Myelofibrosis
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 30
Testing effectiveness (Phase 2)Study completedNCT00639002
What this trial is testing

Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Incyte Corporation 13
Not applicableNot Yet RecruitingNCT06976918
What this trial is testing

Registry Platform Myelofibrosis and Anemia

Who this might be right for
Primary MyelofibrosisSecondary MyelofibrosisPost-polycythemia Vera Myelofibrosis+4 more
iOMEDICO AG 200
Testing effectiveness (Phase 2)Study completedNCT05198310
What this trial is testing

Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Who this might be right for
Arthritis, Rheumatoid
Kiniksa Pharmaceuticals, Ltd. 145
Load More Results